Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial.
Kejing Tang, Fengying Wu, Fang Yang, Yu Yao, Yanqiu Zhao, Jianying Zhou, Ping Sun, Donglin Wang, Dongqing Lv, Huijie Wang, Yi Hu, Qiang Li, Yujiao Song, Grace Gao, Fang Pan, Archan Bhattacharya, Mahadi Baig, Patricia A Lorenzini, Honeylet Wortman-Vayn, Trishala Agrawal, Caicun Zhou
Chin Med J (Engl) 10.1097/CM9.0000000000004134
摘要
摘要
BACKGROUND: First-line amivantamab plus carboplatin-pemetrexed demonstrated efficacy and an acceptable safety profile in the PAPILLON trial (NCT04538664) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertions; we report the efficacy and safety results of the Chinese mainland subgroup population from the PAPILLON study. METHODS: PAPILLON was a randomized, open-label, multicenter, phase 3 study comparing amivantamab plus carboplatin-pemetrexed therapy with standard of care carboplatin-pemetrexed, in patients with treatment-naïve, locally advanced, or metastatic non-small-cell lung cancer characterized by EGFR exon 20 insertion mutations. Between March 2021 and October 2022, 87 treatment-naïve patients were randomized in China (amivantamab plus carboplatin-pemetrexed, 39; carboplatin-pemetrexed, 48). The primary endpoint was progression-free survival as assessed by blinded independent central review according to Response Evaluation Criteria in Solid Tumors v1.1. Comparison between treatment groups was conducted using a stratified log-rank test, with hazard ratios estimated from a stratified Cox proportional hazards model. RESULTS: Progression-free survival was longer in the amivantamab plus carboplatin-pemetrexed group than in the carboplatin-pemetrexed group (median, 12.3 months, 95% confidence interval [CI], 7.0 months to not evaluable vs. 6.7 months, 95% CI, 4.2-8.6 months; hazard ratio, 0.47; 95% CI, 0.26-0.85; nominal P = 0.0109). The 18-month progression-free survival rate was 33% with amivantamab plus carboplatin-pemetrexed and 12% with carboplatin-pemetrexed. The objective response rate was 71.8% (95% CI, 55.1-85.0%) with amivantamab plus carboplatin-pemetrexed and 48.9% (34.1-63.9%) with carboplatin-pemetrexed (odds ratio, 2.46; 95% CI, 1.01-5.98; nominal P = 0.0478). Median progression-free survival after first subsequent therapy was not evaluable for amivantamab plus carboplatin-pemetrexed and 18.8 months for carboplatin-pemetrexed (hazard ratio, 0.32; 95% CI, 0.11-0.88; nominal P = 0.0212). Interim overall survival analysis suggests about 42% improved chance of survival with amivantamab plus carboplatin-pemetrexed vs. carboplatin-pemetrexed. The most common adverse events with amivantamab plus carboplatin-pemetrexed were neutropenia, anemia, leukopenia, and rash. No new safety signals were observed. No patients discontinued amivantamab due to related adverse events. CONCLUSION: Results from the PAPILLON Chinese mainland population were consistent with the overall population and support the use of amivantamab plus carboplatin-pemetrexed in first-line treatment of Chinese patients with EGFR exon 20 insertion-mutated non-small cell lung cancer. TRIAL REGISTRATION: https://clinicaltrials.gov/; registration number, NCT04538664.
KM 提取结果
0 个 Figure · 0 个 KM 面板